Compare CVGI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | ELTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 185.4M |
| IPO Year | 2004 | 2014 |
| Metric | CVGI | ELTX |
|---|---|---|
| Price | $4.51 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 657.7K | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | 39.29 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | $2,301,000.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $110.00 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $1.29 | $2.66 |
| 52 Week High | $5.88 | $16.00 |
| Indicator | CVGI | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 33.88 |
| Support Level | $3.73 | $2.66 |
| Resistance Level | $4.45 | $9.44 |
| Average True Range (ATR) | 0.40 | 0.96 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 8.15 | 4.58 |
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.